Treatment of Thrombocytosis with Hydroxyurea

Indications for Hydroxyurea Treatment

• Hydroxyurea is the first-line cytoreductive therapy for thrombocytosis in high-risk patients with essential thrombocythemia (ET) or polycythemia vera (PV), with a target platelet count below 400 x 10^9/L to reduce thrombotic complications 1, 2, 3
• Cytoreductive therapy with hydroxyurea is indicated in high-risk patients with ET or PV, including those over 60 years of age 2, 3
• Cytoreductive therapy with hydroxyurea is indicated in high-risk patients with ET or PV, including those with history of thrombosis or hemorrhage 3, 4
• Cytoreductive therapy with hydroxyurea is indicated in high-risk patients with ET or PV, including those with platelet count >1,500 x 10^9/L (due to increased bleeding risk) 1, 3

Dosing and Administration

• For patients >80 kg, consider a hydroxyurea dose of 2.5 g/day 1
• Titrate hydroxyurea to achieve target platelet count <400 x 10^9/L 1, 3

Monitoring Response

• Monitor complete blood counts every 4-8 weeks once stabilized 3
• Target response includes platelet count <400 x 10^9/L 1, 3
• Target response includes WBC count <10 x 10^9/L 1
• Target response includes resolution of disease-related symptoms 3
• No routine monitoring of bone marrow response is needed for clinical follow-up 3
• Bone marrow examination is indicated only when assessing for transformation to myelofibrosis or acute leukemia 3

Resistance and Intolerance

• Resistance or intolerance to hydroxyurea is defined by platelet count >600 x 10^9/L after 3 months of adequate hydroxyurea dosing for essential thrombocythemia 5, 4
• Resistance or intolerance to hydroxyurea is defined by presence of leg ulcers or other unacceptable mucocutaneous manifestations for essential thrombocythemia 5, 4
• Resistance or intolerance to hydroxyurea is defined by need for phlebotomy to maintain hematocrit <45% despite 3 months of hydroxyurea for polycythemia vera 5, 4

Second-Line Therapy Options

• For patients resistant or intolerant to hydroxyurea, anagrelide is the recommended second-line therapy for essential thrombocythemia 3, 6
• For patients resistant or intolerant to hydroxyurea, interferon-alpha is the recommended second-line therapy for polycythemia vera 1, 3
• Ruxolitinib may be considered for patients with polycythemia vera resistant or intolerant to hydroxyurea 7, 8

Important Considerations and Cautions

• Young patients (<40 years) should use hydroxyurea with caution due to long-term leukemogenic risk 1, 3
• Aggressively manage cardiovascular risk factors in all patients with ET or PV 3
• Consider interferon-alpha instead of hydroxyurea for pregnant patients requiring cytoreductive therapy 9
• Monitor for common side effects, including mucocutaneous manifestations 5, 4
• Monitor for common side effects, including GI symptoms 5, 4
• Monitor for common side effects, including leg ulcers 5, 4

Essential Thrombocytosis Management with Hydroxyurea

Serious Side Effects and Monitoring

• The National Comprehensive Cancer Network recommends stopping hydroxyurea therapy immediately if absolute neutrophil count falls below 1.0 × 10⁹/L, platelet count below 100 × 10⁹/L, or hemoglobin below 10 g/dL, due to the risk of severe bone marrow suppression 10, 11
• Leg ulcers and painful skin lesions can develop at any dose of hydroxyurea and require immediate discontinuation, as per the National Comprehensive Cancer Network guidelines 10, 11

Treatment Response and Resistance

• The National Comprehensive Cancer Network defines treatment failure as a platelet count remaining above 600 × 10⁹/L after 3 months on adequate doses of hydroxyurea, indicating the need for alternative therapy 10, 11
• Other resistance criteria include platelet count >400 × 10⁹/L with hemoglobin <10 g/dL at any dose, and development of leg ulcers, severe mucocutaneous toxicity, or hydroxyurea-related fever at any dose, as outlined by the National Comprehensive Cancer Network 10, 11

Infection and Vaccination Precautions

• The National Comprehensive Cancer Network advises avoiding live vaccines while on hydroxyurea due to the risk of severe infections, and discussing all planned vaccinations with a hematologist before receiving them 10, 11

Hydroxyurea‑Associated Bleeding in Myeloproliferative Disorders

Acquired von Willebrand Disease in the Setting of Extreme Thrombocytosis

• In patients with essential thrombocythemia or polycythemia vera, bleeding can occur despite normal or elevated platelet counts because hydroxyurea‑induced extreme thrombocytosis (often > 1,000 × 10⁹/L) consumes von Willebrand factor multimers, leading to acquired von Willebrand disease (AVWD). 12
• The National Comprehensive Cancer Network (NCCN) recommends that when bleeding arises in the context of markedly high platelet counts, clinicians should order coagulation studies—including VWF antigen, VWF activity, and ristocetin cofactor assays—to evaluate for AVWD. 13

Pediatric Considerations

• Approximately 20 % of children diagnosed with chronic myeloid leukemia present with bleeding manifestations even though platelet counts are normal or elevated, reflecting AVWD in this population. 12
• In these pediatric patients, the bleeding typically resolves within 2–4 weeks after initiation of tyrosine‑kinase inhibitor therapy, indicating that the AVWD is transient. 12

NCCN Guideline Recommendations for Managing Hydroxyurea‑Related Bleeding

• Aspirin should be used with extreme caution—or avoided—in patients who have acquired VWD because of a markedly increased risk of bleeding. 13
• The NCCN explicitly advises immediate discontinuation of aspirin until bleeding is controlled. 13
• When bleeding occurs despite normal or high platelet counts, the guideline directs clinicians to (1) test for acquired VWD and (2) consider cytoreductive therapy (e.g., dose adjustment of hydroxyurea or alternative agents) to bring platelet counts to a safer range. 13
• The NCCN instructs clinicians to “rule out other potential causes and treat coexisting causes as necessary” whenever bleeding is observed in patients on hydroxyurea. 13
• The guideline warns against continuing aspirin in any patient with confirmed or suspected acquired VWD or active bleeding (reinforced in multiple NCCN statements). 13, 14
• Clinicians should not assume that anemia in hydroxyurea‑treated patients is solely due to marrow suppression; a systematic evaluation for hemolysis and occult bleeding is required. 13